Leadership
As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.
The time is now to prepare your company for AI implementation. Doing so starts with the C-suite.
In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.
Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.
Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?
Ipsen rare diseases head Jennifer Schranz talks to In Vivo about why women are especially susceptible to a “diagnostic odyssey,” and how the company is working to find and treat female zebras.
Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.
Dealmakers from CAR-T biotech Poseida Therapeutics and Astellas recently sat down with In Vivo to discuss how they reached a $600m deal that combines their technologies and how they plan on moving forward.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Health authorities around the world are being advised to mitigate the relentless rise in the long-term costs of stroke, set to top $1.5tn within a generation. Wider availability of mechanical thrombectomy will help address providers’ and patients’ needs, Royal Philips CMO Carla Perón explained in an interview with In Vivo.
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second
The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.
Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics
Christopher Anzalone is spearheading Arrowhead Pharmaceuticals' transformation from a development-focused to a commercial-stage biotech. The CEO touts an “almost plug and play” platform, a derisked development strategy and a busy pipeline with vast potential.
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.
Following the pivotal data on Alnylam’s Amvuttra, all eyes turn to the next amyloidosis readout – that of AstraZeneca and Ionis’ Wainua. And the UK major’s ambitions do not stop there.